Souhaitez-vous accéder aux communiqués récents ?

Boehringer and Jazz Pharma partner to combine two unique HER2-targeted approaches, aiming to offer new breast cancer treatment options.

Athira Pharma, Inc. today announced that it has changed its name to LeonaBio, Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...

- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim...

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endpoint met and encouraging secondary performance...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing...

RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...

Io Therapeutics announced today data demonstrating effectiveness of its RXR agonist IRX4204 for synergistic killing of HER2+ breast cancer with CAR-T cells

Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and...

OAKLAND, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Alameda Health System (AHS) has been honored with the 2025 Quality Leaders Award (QLA) by the California Association of Public Hospitals and...